Aim and Scope of the Call
The call aims to increase scientific understanding and evidence-based knowledge on emerging and re-emerging pathogens with pandemic potential, as well as on host responses triggered by infection.
The scope of JTC2026 primarily addresses Priority 1 of the Strategic Research and Innovation Agenda (SRIA): “Accelerate knowledge in a coordinated and integrative manner.” It focuses on:
- Action 1.1: Increase knowledge on understanding, identifying, and addressing therapeutic targets on pathogens.
- Action 1.2: Increase knowledge on pathophysiology.
Proposals should deliver results contributing to at least one of the following:
- Identification of novel pathogen-specific molecular targets and mutation hotspots (i.e. discovery of critical proteins, enzymes or signalling molecules that play a central role in pathogen infectivity, survival and/or resistance);
- Improving the understanding of cross-species (zoonotic) aspects of host–pathogen interactions (in the context of the One Health approach);
- Application of the “Pathogen X” approach to generate transferable knowledge that can then be applied to other threatening viruses of the same family;
- Identification, development and optimisation of (new) structures with optimal therapeutic activity and low toxicity that can be potential lead compounds (particularly for vulnerable groups);
- Identification and validation of targets, alongside data integration, interoperability and modelling efforts to demonstrate the potential of these targets, including antigenic structures suitable for vaccine development, for subsequent therapeutic development (i.e. proof-of-concept studies);
- Improving data integration and modelling to predict pathogen behaviour and therapeutic susceptibilities;
- Understanding the molecular and cellular mechanisms underlying host-pathogen interactions, in humans including host predisposing factors, to guide future diagnostic, therapeutic and vaccine development;
- Development and improvement of advanced immunological assays, experimental models and preclinical studies that link host genetics to disease outcomes.
Proposals must focus exclusively on one or more viruses from the following families:
Arenaviridae, Coronaviridae, Filoviridae, Flaviviridae, Hantaviridae, Nairoviridae, Orthomyxoviridae, Paramyxoviridae, Phenuiviridae, Poxviridae, Togaviridae, or “Pathogen X.”
Proposals addressing global approaches towards a whole family of these pathogens are also feasible.
Proposals must be hypothesis-driven with a strong focus on reliable and rigorous methodology. Consortia should be interdisciplinary, bringing together expertise from diverse fields such as clinical research, bioinformatics, veterinary science, public health, and social sciences. The added value of the transnational and interdisciplinary collaboration must be clearly demonstrated. Research plans should also integrate sex, gender, and diversity considerations.
Additionally, proposals are encouraged to address specific populations or vulnerable groups, incorporate highly innovative methodologies or state-of-the-art technologies, foster collaboration with private sector partners, and leverage existing cohorts and datasets.
Excluded topics and activities:
- Antimicrobial resistant (AMR) pathogens (resistant to antibiotics and antifungal agents).
- Research addressing SRIA priority actions 1.3 (Increase knowledge on environmental and social aspects driving pathogen emergence) and 1.4 (Increase knowledge on transmission dynamics and epidemiology);
- Clinical studies (covering clinical studies/trials/investigations/cohorts)